Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Preface457
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future406
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”279
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus215
Approaches to quantifying hepatitis B virus covalently closed circular DNA194
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?139
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity129
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer128
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"98
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation97
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)96
Contemporary Trends in Extrahepatic Mortality of Chronic Liver Disease in the United States from 2014 to 202392
An editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” by Hong et al.85
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases81
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials76
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign71
Letter “GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study”71
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis69
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity69
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A61
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”61
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target60
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease58
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c56
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–202354
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study54
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”54
Toward hepatitis C virus elimination using artificial intelligence53
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis53
Liver organoids: Current advances and future applications for hepatology51
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial50
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease44
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment44
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma44
HCC Surveillance After Curative Treatment: A New Frontier for Abbreviated MRI Editorial on: “Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: Compari44
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma43
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma43
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate42
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe42
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”41
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs41
0.98526096343994